60 Vegetarian Capsules ( SKU: 9411, NPN: 80049716 )

Benefits

Prepared using a natural enzyme process that attaches polysaccharides to convert quercetin into a soluble form

Capsules suitable for vegetarians/vegans

Feature Summary

Quercetin, a dietary flavonol known to be one of the most potent plant-derived antioxidants, has multiple biological actions, with anti-inflammatory, anti-thrombotic and vasodilatory benefits in pre-clinical studies.1 However, clinical trials have not consistently matched expected results based upon pre-clinical studies.

The limiting factor in quercetin’s clinical efficacy appears to be its poor bioavailability. Enzymatically modified isoquercitrin (EMIQ) is a mixture of quercetin monoglucoside and its alpha-oligoglucosides that has been shown to have significantly greater bioavailability than other available forms. In animals, EMIQ was shown to produce a 40 fold increase in Cmax (peak plasma concentration) and an 18-fold increase in the area under the curve compared to quercetin.2 In humans, EMIQ supplementation increased plasma concentrations to a significantly greater degree than other forms,3 including aglycone and isoquercitrin, with randomized placebo-controlled trials documenting improvement in allergic symptoms.4,5 EMIQ has also shown significantly enhanced biological activity especially in animal models of allergy and neoplasia.6

EMIQ has shown significant effects in improving ocular symptoms of hay fever in doubleblind clinical studies. In one study, 20 subjects with hay fever due to Japanese cedar pollinosis took two capsules daily of 100 mg EMIQ or a placebo for 8 weeks during the pollen season.7 During the entire study period, total ocular score and ocular itching score for the EMIQ group were significantly lower than the placebo group. In another study of hay fever due to Japanese cedar pollinosis, 24 subjects took 100 mg EMIQ or a placebo for 8 weeks, starting 4 weeks prior to the onset of pollen release.8 During the entire study period, ocular symptom and medication scores for the EMIQ group was significantly lower than the placebo group. When limited to the pollen release period, ocular symptom and ocular congestion scores for the EMIQ group were significantly lower than the placebo group. Other scores for the EMIQ group, such as ocular itching scores, lacrimation scores, and ocular congestion scores, all tended to be lower.